skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Details
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Reel/Frame:061149/0356   Pages: 26
Recorded: 08/11/2022
Attorney Dkt #:108407-1281309-018WO1
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE THE SPELLING OF THE FIRST INVENTOR'S NAME PREVIOUSLY RECORDED ON REEL 059436 FRAME 0280. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Total properties: 1
1
Patent #:
NONE
Issue Dt:
Application #:
17753594
Filing Dt:
03/09/2022
Publication #:
US20220332780
Pub Dt:
10/20/2022
PCT #:
US2020050273
Title:
CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
Assignors
1
ELPEK, KUTLU GOKSU
Exec Dt:
03/30/2021
2
SETHI, DHRUV KAM
Exec Dt:
03/30/2021
3
LANGLEY, MEGHAN C.
Exec Dt:
03/29/2021
4
EZELL, TUCKER READ
Exec Dt:
04/08/2021
5
SUN, DEXUE
Exec Dt:
03/29/2021
6
GORI, JENNIFER LEAH
Exec Dt:
04/06/2021
7
MYLVAGANAM, GEETHA HANNA
Exec Dt:
03/28/2021
8
OLS, MICHELLE
Exec Dt:
03/28/2021
9
FLEURY, MICHELLE
Exec Dt:
10/09/2020
10
RICHARDSON, CELESTE
Exec Dt:
03/27/2021
11
STORER, JAMES A.
Exec Dt:
04/01/2021
12
SURI, VIPIN
Exec Dt:
04/01/2021
13
SUBRAMANIAN, SHYAMSUNDAR
Exec Dt:
03/30/2021
14
FOLEY, COLLEEN
Exec Dt:
03/29/2021
15
PERKINS, MOLLY REED
Exec Dt:
04/09/2021
16
TCHAICHA, JEREMY HATEM
Exec Dt:
03/29/2021
17
HELLER, SCOTT FRANCIS
Exec Dt:
03/27/2021
Assignee
1
OBSIDIAN THERAPEUTICS, INC.
1030 MASSACHUSETTS AVENUE
SUITE 400
CAMBRIDGE, MASSACHUSETTS 02138
Correspondence name and address
KILPATRICK TOWNSEND & STOCKTON LLP
1100 PEACHTREE STREET NE
SUITE 2800
ATLANTA, GA 30309

Search Results as of: 05/25/2024 01:17 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT